Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 4
2019 6
2020 3
2021 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean sport consortium[Corporate Author] (447 results)?
Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy Showcase.
Yiu ZZN, Barker JNWN, Barnes MR, Di Meglio P, Emsley R, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM; PSORT Consortium. Yiu ZZN, et al. J Invest Dermatol. 2021 Aug;141(8):1872-1878. doi: 10.1016/j.jid.2021.02.746. Epub 2021 Mar 24. J Invest Dermatol. 2021. PMID: 33771529 Free article.
Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.
Andres-Ejarque R, Ale HB, Grys K, Tosi I, Solanky S, Ainali C, Catak Z, Sreeneebus H, Saklatvala J, Dand N, de Rinaldis E, Chapman A, Nestle FO, Barnes MR, Warren RB, Reynolds NJ, Griffiths CEM, Barker JN, Smith CH, Di Meglio P; PSORT Consortium. Andres-Ejarque R, et al. Nat Commun. 2021 Aug 6;12(1):4741. doi: 10.1038/s41467-021-25066-9. Nat Commun. 2021. PMID: 34362923 Free PMC article.
Defining trajectories of response in patients with psoriasis treated with biologic therapies.
Geifman N, Azadbakht N, Zeng J, Wilkinson T, Dand N, Buchan I, Stocken D, Di Meglio P, Warren RB, Barker JN, Reynolds NJ, Barnes MR, Smith CH, Griffiths CEM, Peek N; BADBIR Study Group, on behalf of the PSORT Consortium. Geifman N, et al. Br J Dermatol. 2021 Oct;185(4):825-835. doi: 10.1111/bjd.20140. Epub 2021 Jun 4. Br J Dermatol. 2021. PMID: 33829489
Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study.
Loeff FC, Tsakok T, Dijk L, Hart MH, Duckworth M, Baudry D, Russell A, Dand N, van Leeuwen A, Griffiths CEM, Reynolds NJ, Barker J, Burden AD, Warren RB, de Vries A, Bloem K, Wolbink GJ, Smith CH, Rispens T; BADBIR; BSTOP Study Groups; PSORT consortium. Loeff FC, et al. J Invest Dermatol. 2020 Nov;140(11):2129-2137. doi: 10.1016/j.jid.2020.03.957. Epub 2020 Apr 10. J Invest Dermatol. 2020. PMID: 32283057 Free article.
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study.
Pan S, Tsakok T, Dand N, Lonsdale DO, Loeff FC, Bloem K, de Vries A, Baudry D, Duckworth M, Mahil S, Pushpa-Rajah A, Russell A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, David Burden A, Rispens T, Standing JF, Smith CH; BADBIR Study Group, the BSTOP Study Group, the PSORT Consortium. Pan S, et al. Clin Transl Sci. 2020 Mar;13(2):400-409. doi: 10.1111/cts.12725. Epub 2020 Jan 29. Clin Transl Sci. 2020. PMID: 31995663 Free PMC article.
HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.
Dand N, Duckworth M, Baudry D, Russell A, Curtis CJ, Lee SH, Evans I, Mason KJ, Alsharqi A, Becher G, Burden AD, Goodwin RG, McKenna K, Murphy R, Perera GK, Rotarescu R, Wahie S, Wright A, Reynolds NJ, Warren RB, Griffiths CEM, Smith CH, Simpson MA, Barker JN; BADBIR Study Group; BSTOP Study Group; PSORT Consortium. Dand N, et al. J Allergy Clin Immunol. 2019 Jun;143(6):2120-2130. doi: 10.1016/j.jaci.2018.11.038. Epub 2018 Dec 20. J Allergy Clin Immunol. 2019. PMID: 30578879 Free article.
Author Correction: Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.
Andres-Ejarque R, Ale HB, Grys K, Tosi I, Solanky S, Ainali C, Catak Z, Sreeneebus H, Saklatvala J, Dand N, de Rinaldis E, Chapman A, Nestle FO, Barnes MR, Warren RB, Reynolds NJ, Griffiths CEM, Barker JN, Smith CH, Di Meglio P; PSORT Consortium. Andres-Ejarque R, et al. Nat Commun. 2021 Dec 16;12(1):7358. doi: 10.1038/s41467-021-27447-6. Nat Commun. 2021. PMID: 34916493 Free PMC article. No abstract available.
Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study.
Wilkinson N, Tsakok T, Dand N, Bloem K, Duckworth M, Baudry D, Pushpa-Rajah A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C; BSTOP study group; PSORT consortium. Wilkinson N, et al. J Invest Dermatol. 2019 Jan;139(1):115-123. doi: 10.1016/j.jid.2018.07.028. Epub 2018 Aug 18. J Invest Dermatol. 2019. PMID: 30130616 Free PMC article.
13 results